Warning: The NCBI web site requires JavaScript to function. more...
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
Morrow PK, Zambrana F, Esteva FJ.
Breast Cancer Res. 2009;11(4):207. Epub 2009 Jul 15. Review.
Related citations
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
Miles DW.
Breast Cancer Res. 2009;11(4):208. Epub 2009 Aug 28.
Update on HER-kinase-directed therapy in prostate cancer.
Gross ME, Jo S, Agus DB.
Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Review.
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R, O'Regan RM.
Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. Review.
Ten years of HER2-directed therapy: still questions after all these years.
Krop IE, Winer EP.
Breast Cancer Res Treat. 2009 Jan;113(2):207-9. Epub 2008 May 8. No abstract available.
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.
Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ, Pusztai L.
Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.
HER2-positive breast cancer: beyond trastuzumab.
Murphy CG, Fornier M.
Oncology (Williston Park). 2010 Apr 30;24(5):410-5. Review.
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL, de Azambuja E, Cardoso F.
Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. Review.
PTEN status in advanced colorectal cancer treated with cetuximab.
Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A.
Br J Cancer. 2010 Jan 5;102(1):162-4. Epub 2009 Dec 1.
Evolving novel anti-HER2 strategies.
Jones KL, Buzdar AU.
Lancet Oncol. 2009 Dec;10(12):1179-87. Review.
Progression and treatment of HER2-positive breast cancer.
Davoli A, Hocevar BA, Brown TL.
Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. Epub 2009 Dec 20.
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL, Andersson M, Kamby C.
Cancer Treat Rev. 2009 Apr;35(2):121-36. Epub 2008 Nov 12. Review.
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F.
Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62. Review.
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA, Stein S.
Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. Epub 2008 Jul 1. Review.
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.
Breast Cancer Res Treat. 2009 Nov;118(1):113-24. Epub 2009 May 5.
HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R, Wenzel C, Zielinski CC, Steger GG.
BioDrugs. 2007;21(2):69-77. Review.
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.
Breast Cancer Res. 2009;11(4):R50. Epub 2009 Jul 22.
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J, Swain SM.
Clin Breast Cancer. 2010 Dec 1;10(6):489-91.
Trastuzumab and breast cancer: developments and current status.
Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y.
Int J Clin Oncol. 2006 Jun;11(3):199-208. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on